Center for Translational Pediatric Research (CTPR)

转化儿科研究中心 (CTPR)

基本信息

批准号：
10380963
负责人：
Alan Tackett
金额：
$ 77万
依托单位：
ARKANSAS CHILDREN'S HOSPITAL RES INST
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-07-11 至 2023-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10380963
关键词：
2019-nCoV Adult Age Arkansas Back Baptist Church Bioinformatics Biomedical Research Blood Circulation COVID-19 monitoring COVID-19 surveillance Categories Centers for Disease Control and Prevention (U.S.)Centers of Research Excellence Child Clinical Code Collaborations Collection County Data Data Analyses Databases Deposition Diagnostic Disease Environment Ethnic Origin Evaluation Future Gender Genome Genomics Geographic Locations Goals Grant Health Health Policy Infection Infrastructure Interdisciplinary Study Measures Medical Monitor Names Patients Pediatric Hospitals Pediatric Research Population Positioning Attribute Public Health Race Reporting Research Research Institute Research Project Grants Running Rural SARS-CoV-2 B.1.1.7 SARS-CoV-2 genome SARS-CoV-2 positive SARS-CoV-2 variant Sampling Science Scientist Secure Symptoms Systems Biology Techniques Technology Testing Time Translational Research Universities Vaccination Vaccines Variant Viral Virus Writing age group base biobank burden of illness coronavirus disease data dissemination demographics feasibility testing meetings multiple omics pandemic disease parent grant racial and ethnic residence respiratory virus sex study population success surveillance data variants of concern

项目摘要

PROJECT SUMMARY The continuing emergence and subsequent circulation of SARS-CoV-2 variants across the world is of concern for the global effort of controlling the Coronavirus Disease (COVID)-19 pandemic. Despite a high-burden of disease overall, Arkansas has been slow to sequence viruses associated with infections in the state. For this proposal, our Center for Translational Pediatric Research (CTPR) Center of Biomedical Research Excellence (COBRE) and Arkansas IDeA Network of Biomedical Research Excellence (INBRE) have partnered together to deliver sustainable SARS CoV-2 genomic surveillance data and analyses for the State of Arkansas. At the core of this proposal, we have built a powerful collaboration named the Arkansas Sequencing (ArkSeq) Consortium which includes the University of Arkansas for Medical Sciences (UAMS), Arkansas Children’s Hospital (ACH), including Arkansas Children’s Northwest and UAMS Northwest extensions, Baptist Health (BH) in Little Rock, drive-through centers across the State run by the Arkansas Department of Health (ADH), and Arkansas Children’s Research Institute (ACRI). This consortium provides remnant viral transport media (VTM) that have been identified as positive for SARS-CoV-2. Our objective is to continuously monitor these samples for SARS- CoV-2 sequence diversity and viral phylodynamics and to provide actionable data back to the ADH and CDC regarding variants. Aim 1 of this proposal is to provide genomic surveillance for Arkansas. To fulfill this aim, we will use Illumina-based platforms to sequence at least 12288 samples from our ArkSeq Consortium for variants of concern (VoCs) over the next year with a goal to scale to all patients. We will obtain clinical information on these samples, including the subject’s demographics (age, sex, race, ethnicity, county of residence, and zip code), date of collection, symptoms at the time of sampling, other respiratory viruses present at the time of positive result, and vaccination status (vaccine type and date of vaccination). This approach will allow us to answer the research questions: “What are the relative levels of the different variants in Arkansas?”; “How does this change over time?” and “How are different Arkansas variants distributed across different geographical regions, as well among racial, ethnic, gender, and/or age groups?” In collaboration with the ADH and the CDC, we will integrate VoCs and other lineages from Arkansas into national databases. We plan to provide actionable sequencing information on current strains of SARS-CoV-2 that are circulating within Arkansas. To meet this goal, we are currently participating in the weekly SPHERES calls with CDC, and we are partnering with ADH and ArkSeq partners to have monthly meetings regarding identified variants. Upon successful completion of this proposal, we will have provided ~21 times more sequences from Arkansas to the databases than are currently available from our State, with many other samples maintained for future evaluation.

项目概要 SARS-CoV-2 变种在世界各地的持续出现和随后的传播令人担忧尽管面临着沉重的负担，但仍致力于全球控制冠状病毒病（COVID）-19大流行。总体而言，阿肯色州对该州感染相关病毒的测序进展缓慢。提案，我们的转化儿科研究中心 (CTPR) 生物医学研究卓越中心 (COBRE) 和阿肯色州 IDeA 生物医学研究卓越网络 (INBRE) 合作，为阿肯色州提供可持续的 SARS CoV-2 基因组监测数据和分析。根据该提案，我们建立了一个强大的合作组织，名为阿肯色测序 (ArkSeq) 联盟其中包括阿肯色医学大学 (UAMS)、阿肯色儿童医院 (ACH)、包括阿肯色州儿童西北分院和 UAMS 西北分院、小石城的浸信会健康中心 (BH)、由阿肯色州卫生部 (ADH) 和阿肯色州运营的全州免下车中心儿童研究所 (ACRI) 提供残留病毒传输介质 (VTM)。被鉴定为 SARS-CoV-2 阳性，我们的目标是持续监测这些样本中的 SARS- CoV-2 序列多样性和病毒系统动力学，并向 ADH 和 CDC 提供可操作的数据该提案的目标 1 是为阿肯色州提供基因组监测。将使用基于 Illumina 的平台对来自 ArkSeq 联盟的至少 12288 个样本进行变体测序明年关注的问题（VoC），目标是扩展到所有患者，我们将获得有关的临床信息。这些样本，包括受试者的人口统计数据（年龄、性别、种族、民族、居住县和邮政编码）代码）、采集日期、采样时的症状、采样时存在的其他呼吸道病毒阳性结果和疫苗接种状态（疫苗类型和疫苗接种日期）。回答研究问题：“阿肯色州不同变体的相对水平是多少？”；这种变化随着时间的推移？”和“不同的阿肯色州变体如何分布在不同的地理区域与 ADH 和 CDC 合作，我们将把来自阿肯色州的 VoC 和其他谱系整合到国家数据库中。我们计划提供可操作的信息。为满足这一要求，我们对阿肯色州当前流行的 SARS-CoV-2 病毒株进行了测序。目标，我们目前正在参加与 CDC 举行的每周 SPHERES 电话会议，并且我们正在与 ADH 合作成功完成此任务后，ArkSeq 合作伙伴将每月召开一次有关已识别变体的会议。根据提案，我们将从阿肯色州向数据库提供的序列数量将比目前多约 21 倍可以从我们州获得，并保留许多其他样本以供将来评估。